ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 8.9% during trading on Thursday . The stock traded as low as GBX 3.33 and last traded at GBX 3.33. Approximately 1,838,091 shares were traded during trading, a decline of 36% from the average session volume of 2,850,241 shares. The stock had previously closed at GBX 3.65.
ImmuPharma Stock Performance
The stock’s fifty day simple moving average is GBX 4.31 and its two-hundred day simple moving average is GBX 5.61. The stock has a market capitalization of £20.78 million, a P/E ratio of -9.00 and a beta of 3.00.
ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
